The in vitro activities of three new P-lactam antimicrobial agents, cefodizime, ceftazidime, and aztreonam (formerly azthreonam), were compared with those of cefotaxime, cefuroxime, cefoxitin, and penicillin against 100 3-lactamase-negative and 42 13-lactamase-positive Neisseria gonorrhoeae strains. The three new antimicrobial agents showed excellent activity against N. gonorrhoeae regardless of P-lactamase production. Cefodizime 
antimicrobial agents showed excellent activity against N. gonorrhoeae regardless of P-lactamase production. Cefodizime was as active as cefotaxime and more active than the other test antimicrobial agents. It inhibited all isolates at a concentration of <0.016 ,ug/ml. Cefodizime, ceftazidime, and aztreonam (formerly azthreonam) are new parenteral P-lactam antimicrobial agents which are highly active in vitro against a broad spectrum of microorganisms (2, 3, 5) . This study was Table 2 . Cefodizime and cefotaxime were also highly effective against this group. All strains were inhibited at a concentration of 0.016 ,ug/ml. Ceftazidime and aztreonam were essentially equal to cefodizime and cefotaxime in their activities against this group. Ceftazidime and aztreonam MICs for 90% of the isolates were twofold and fourfold higher, respectively, than those of cefodizime and cefotaxime. Cefuroxime was less active than the aforementioned antimicrobial agents; however, it was more active than cefoxitin against these isolates. As expected, 1-lactamase-positive isolates were highly resistant to penicillin.
Our in vitro results demonstrate that the new 3-lactam antimicrobial agents cefodizime, ceftazidime, and aztreonam are highly active against N. gonorrhoeae regardless of ,B-lactamase production. Their in vitro activities against N. gonorrhoeae compares favorably with those of cefotaxime, cefuroxime, and cefoxitin, which are presently in use for gonococcal infections.
In a preliminary report, aztreonam has been shown to be effective in urethritis due to 1- In view of the excellent in vitro activity of these new ,B-lactam antimicrobial agents, clinical trials to verify their efficacy in treating gonococcal infections are warranted.
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